Phase I trial of emavusertib IRAK4/FLT3 inhibitor with gemcitabine and nab-paclitaxel

This Phase I study evaluates the safety and optimal dosing of emavusertib combined with gemcitabine and nab-paclitaxel in patients with metastatic or unresectable pancreatic ductal adenocarcinoma. Sponsored by the National Cancer Institute, the trial explores whether this novel approach can improve outcomes in a population with limited treatment options.